Skip to main content

Table 2 Schedule of enrolment, interventions, and assessments of the control arm

From: Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6)

  Study period
Enrolment/allocation Post-allocation Close-out
Outpatient clinics CRS-HIPEC 3 months after CRS-HIPEC 6 months after CRS-HIPEC 9 months after CRS-HIPEC 12 months after CRS-HIPEC Every 6 months 5 years after randomisation
 Eligibility screen X        
 Informed consent X        
 Allocation X        
 CRS-HIPEC   X       
 Thoracoabdominal CT    X X   X X X
 Questionnaires X   X X X X X X
 Translational research: blood X Xa X X   X X X
 Translational research: tissue   X       
 Baseline characteristics X        
 Surgical characteristics   X       
 Postoperative morbidity   X X      
 Progression-free survival   X X X X X X X
 Disease-free survival   X X X X X X X
 Overall survival   X X X X X X X
 Health-related quality of life X X X X X X X X
 Costs X X X X X X X X
  1. a1 day before CRS-HIPEC and 7 days after CRS-HIPEC; CRS-HIPEC cytoreductive surgery with hyperthermic intraperitoneal chemotherapy, CT computed tomography